Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1 results about "Lacidipine" patented technology

Lacidipine (tradenames Lacipil or Motens) is a calcium channel blocker. It is available as tablets containing 2 or 4 mg. It was patented in 1984 and approved for medical use in 1991.

Use of dihydropyridine compounds or salts thereof for the preparation of a medicament for the prevention and / or treatment of HPV infection

ActiveCN120459096BOrganic active ingredientsAntiviralsLacidipineNimodipine
The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.
Owner:QINGDAO MARINE BIOPHARMACEUTICAL RES INST